Clinical Study "Common" Name (formal title)	Number of enrollees	Funding source (pharmaceutical company/National Institutes of Health [NIH])	Year complete	Primary publication	Full study treatment protocol/patient disposition
HAWK and HARRIER (HAWK and HARRIER: Ninety-Six-Week Outcomes from the Phase 3 Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration)	HAWK: 1078 HARRIER: 739	Alcon (HAWK: NCT02307682) (HARRIER: NCT02434328)	HAWK: 2020 HARRIER: 2020	Dugel PU, et al. Ophthalmology. 2021;128:189-199. https://www.aaojournal.org/article/S0161-6420(20)30570-4/fulltext	See primary HAWK/HARRIER summary [Dugel.Ophthalmology.2020]